Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

DRAK2 anticorps (C-Term)

STK17B Reactivité: Humain, Souris WB, IF, IHC (p) Hôte: Lapin Polyclonal RB3049 unconjugated
N° du produit ABIN1882073
  • Antigène Voir toutes DRAK2 (STK17B) Anticorps
    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
    Épitope
    • 10
    • 7
    • 6
    • 6
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 342-371, C-Term
    Reactivité
    • 41
    • 15
    • 8
    • 1
    • 1
    • 1
    Humain, Souris
    Hôte
    • 38
    • 2
    • 1
    Lapin
    Clonalité
    • 40
    • 1
    Polyclonal
    Conjugué
    • 20
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp DRAK2 est non-conjugé
    Application
    • 29
    • 25
    • 8
    • 3
    • 3
    • 2
    • 2
    Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Purification
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogène
    This DRAK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 342-371 amino acids from the C-terminal region of human DRAK2.
    Clone
    RB3049
    Isotype
    Ig Fraction
    Top Product
    Discover our top product STK17B Anticorps primaire
  • Indications d'application
    IF: 1:10~50. WB: 1:1000. IHC-P: 1:50~100
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Date de péremption
    6 months
  • Mao, Luo, Han, Bertrand, Wu: "Drak2 is upstream of p70S6 kinase: its implication in cytokine-induced islet apoptosis, diabetes, and islet transplantation." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 8, pp. 4762-70, (2009) (PubMed).

    Mao, Qiao, Luo, Wu: "Transgenic drak2 overexpression in mice leads to increased T cell apoptosis and compromised memory T cell development." dans: The Journal of biological chemistry, Vol. 281, Issue 18, pp. 12587-95, (2006) (PubMed).

    Sanjo, Kawai, Akira: "DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis." dans: The Journal of biological chemistry, Vol. 273, Issue 44, pp. 29066-71, (1998) (PubMed).

  • Antigène
    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
    Autre désignation
    DRAK2 (STK17B Produits)
    Synonymes
    anticorps zgc:65989, anticorps STK17B, anticorps DRAK2, anticorps Drak2, anticorps 3110009A03Rik, anticorps AI120141, anticorps serine/threonine kinase 17b (apoptosis-inducing), anticorps serine/threonine kinase 17b, anticorps stk17b, anticorps STK17B, anticorps Stk17b
    Sujet
    DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.
    Poids moléculaire
    42344
    NCBI Accession
    NP_004217
    UniProt
    O94768
Vous êtes ici:
Support technique